Adaptimmune Therapeutics plc (F:473A) — Stock Price
Adaptimmune Therapeutics plc (F:473A) is currently trading at €0.16 EUR, up 6.58% today. Over the past 52 weeks, shares have ranged between €0.03 and €0.25. This page tracks Adaptimmune Therapeutics plc's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Adaptimmune Therapeutics plc market cap and net worth.
Adaptimmune Therapeutics plc (473A) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Adaptimmune Therapeutics plc's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
Adaptimmune Therapeutics plc Income Statement — Revenue, Profit & Earnings by Year
Adaptimmune Therapeutics plc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €178.03 Million | €60.28 Million | €27.15 Million | €6.15 Million | €3.96 Million |
| Cost of Revenue | €70.00K | €0.00 | €0.00 | — | — |
| Gross Profit | €177.96 Million | €60.28 Million | €27.15 Million | — | — |
| Research & Development | €149.06 Million | €126.51 Million | €127.73 Million | €111.09 Million | €91.57 Million |
| SG&A | €81.31 Million | €71.81 Million | €63.39 Million | €59.46 Million | €46.99 Million |
| Total Operating Expenses | €230.44 Million | €198.32 Million | €191.11 Million | €168.40 Million | €137.36 Million |
| Operating Income | €-52.41 Million | €-138.04 Million | €-163.97 Million | €-162.25 Million | €-133.41 Million |
| EBITDA | — | — | €-157.89 Million | €-155.68 Million | €-125.81 Million |
| EBIT | — | — | €-161.67 Million | €-162.25 Million | €-133.41 Million |
| Interest Expense | €3.35 Million | €0.00 | €0.00 | €0.00 | €0.00 |
| Income Before Tax | €-67.24 Million | €-112.53 Million | €-162.96 Million | €-157.30 Million | €-129.93 Million |
| Income Tax Expense | — | — | €2.50 Million | €791.00K | €162.00K |
| Net Income | €-70.81 Million | €-113.87 Million | €-165.46 Million | €-158.09 Million | €-130.09 Million |
Adaptimmune Therapeutics plc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Adaptimmune Therapeutics plc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €245.96 Million | €282.62 Million | €328.92 Million | €469.55 Million | €451.14 Million |
| Total Current Assets | €188.17 Million | €207.55 Million | €255.37 Million | €415.46 Million | €398.15 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €60.47 Million | €2.95 Million | €96.57 Million | €219.63 Million | €311.33 Million |
| Net Receivables | €1.45 Million | €821.00K | €7.43 Million | €752.00K | €139.00K |
| Inventory | €7.32 Million | €0.00 | €1.28 Million | €746.00K | €2.09 Million |
| Property, Plant & Equipment | — | — | €71.53 Million | €51.37 Million | €46.66 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €234.11 Million | €243.10 Million | €247.04 Million | €263.58 Million | €109.92 Million |
| Total Current Liabilities | €64.53 Million | €72.79 Million | €64.50 Million | €62.54 Million | €39.07 Million |
| Long-term Debt | €50.24 Million | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | €11.85 Million | €39.51 Million | €81.88 Million | €205.96 Million | €341.23 Million |
| Retained Earnings | €-1.09 Billion | €-1.02 Billion | €-909.30 Million | €-743.85 Million | €-585.76 Million |
Adaptimmune Therapeutics plc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Adaptimmune Therapeutics plc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-73.21 Million | €-140.88 Million | €-141.77 Million | €10.73 Million | €-53.59 Million |
| Capital Expenditures | €2.72 Million | €4.88 Million | €29.50 Million | €8.57 Million | €2.34 Million |
| Free Cash Flow | €-75.93 Million | €-145.76 Million | €-171.51 Million | €1.95 Million | €-56.50 Million |
| Investing Cash Flow | — | — | €89.14 Million | €75.80 Million | €-278.92 Million |
| Financing Cash Flow | €78.75 Million | €880.00K | €12.87 Million | €3.29 Million | €340.05 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €12.05 Million | €11.77 Million | €18.24 Million | €20.63 Million | €10.41 Million |
| Depreciation | €11.22 Million | €9.84 Million | €6.08 Million | €6.57 Million | €7.59 Million |
| Change in Cash | €-53.81 Million | €37.41 Million | €-42.06 Million | €90.18 Million | €6.58 Million |
Adaptimmune Therapeutics plc Earnings History — EPS Actual vs. Analyst Estimates
Track Adaptimmune Therapeutics plc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 11, 2026 | — | — | — |
| Mar 18, 2026 | — | — | — |
| Nov 25, 2025 | — | -0.12 | — |
| Aug 14, 2025 | — | -0.13 | — |
| May 13, 2025 | — | — | — |
| Aug 09, 2023 | -0.11 | — | — |
| May 12, 2023 | 0.01 | — | — |
| Mar 06, 2023 | -0.17 | — | — |